Novacyt Financials
| ALNOV Stock | EUR 0.58 0.01 1.75% |
Novacyt |
Understanding current and past Novacyt Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Novacyt's financial statements are interrelated, with each one affecting the others. For example, an increase in Novacyt's assets may result in an increase in income on the income statement.
Novacyt Stock Summary
Novacyt competes with Cellectis, and Innate Pharma. Novacyt S.A. develops and sells diagnostic products for cancer and infectious diseases. The company was founded in 2006 and is based in Vlizy-Villacoublay, France. NOVACYT operates under Biotechnology classification in France and is traded on Paris Stock Exchange. It employs 111 people.| Instrument | France Stock View All |
| Exchange | Euronext Paris |
| ISIN | FR0010397232 |
| Business Address | 13 Avenue Morane |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.novacyt.com |
| Phone | 33 1 39 46 51 04 |
| Currency | EUR - Euro |
You should never invest in Novacyt without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Novacyt Stock, because this is throwing your money away. Analyzing the key information contained in Novacyt's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Novacyt Key Financial Ratios
Novacyt's financial ratios allow both analysts and investors to convert raw data from Novacyt's financial statements into concise, actionable information that can be used to evaluate the performance of Novacyt over time and compare it to other companies across industries.| Return On Equity | -0.0198 | |||
| Return On Asset | 0.0145 | |||
| Target Price | 4.1 | |||
| Number Of Employees | 210 | |||
| Beta | -2.16 |
Novacyt Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Novacyt's current stock value. Our valuation model uses many indicators to compare Novacyt value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Novacyt competition to find correlations between indicators driving Novacyt's intrinsic value. More Info.Novacyt is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Novacyt's earnings, one of the primary drivers of an investment's value.Novacyt Systematic Risk
Novacyt's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Novacyt volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was ten with a total number of output elements of fifty-one. The Beta measures systematic risk based on how returns on Novacyt correlated with the market. If Beta is less than 0 Novacyt generally moves in the opposite direction as compared to the market. If Novacyt Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Novacyt is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Novacyt is generally in the same direction as the market. If Beta > 1 Novacyt moves generally in the same direction as, but more than the movement of the benchmark.
Novacyt December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Novacyt help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Novacyt. We use our internally-developed statistical techniques to arrive at the intrinsic value of Novacyt based on widely used predictive technical indicators. In general, we focus on analyzing Novacyt Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Novacyt's daily price indicators and compare them against related drivers.
| Information Ratio | (0.21) | |||
| Maximum Drawdown | 27.38 | |||
| Value At Risk | (8.45) | |||
| Potential Upside | 6.78 |
Additional Tools for Novacyt Stock Analysis
When running Novacyt's price analysis, check to measure Novacyt's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Novacyt is operating at the current time. Most of Novacyt's value examination focuses on studying past and present price action to predict the probability of Novacyt's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Novacyt's price. Additionally, you may evaluate how the addition of Novacyt to your portfolios can decrease your overall portfolio volatility.